Showing results (141-150 of 157) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 8, 2014
EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic surveyYasushi Yatabe, Keith M Kerr, Ahmad Utomo, et al.Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 11, 2021
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, Philip Mack, Giorgio V Scagliotti, et al.Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.CA: a Cancer Journal for Clinicians|March 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 studyJian-Chun Duan, Jia Zhong, Bo-Yang Sun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.Pageof 16